Tocilizumab Spirig HC
Tocilizumab Spirig HC is a biosimilar from Spirig HealthCare AG and is listed on the FOPH Specialities List. As the follow-on product of a biologic it is reimbursed by basic health insurance. The public price ranges from CHF 108.15 to CHF 475.05 depending on the pack; the co-payment is 10 per cent.
Core data
- Authorisation holder
- Spirig HealthCare AG
- ATC code
- L04AC07
- IT group
- 07.15 Immunosuppressive Stoffe
- Active substances
- Tocilizumabum
- Preparation type
- Biosimilar
- On the SL since
- 01/04/2026
- Last price change
- 01/04/2026
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Inf Konz 80 mg/4ml | Durchstf 1 Stk | CHF 84.34 | CHF 108.15 | 01/04/2026 | A | 7680699250073 |
| Inf Konz 200 mg/10ml | Durchstf 1 Stk | CHF 210.85 | CHF 245.75 | 01/04/2026 | A | 7680699250097 |
| Inf Konz 400 mg/20ml | Durchstf 1 Stk | CHF 421.71 | CHF 475.05 | 01/04/2026 | A | 7680699250110 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
Zur Behandlung der aktiven rheumatoiden Arthritis bei erwachsenen Patienten, die auf die Behandlung mit einem konventionellen synthetischen DMARD (disease-modifying antirheumatic drugs) oder einem Tumornekrosefaktor (TNF)-Hemmer nicht ausreichend angesprochen haben.
In Kombination mit Kortikosteroiden und konventionellen synthetischen DMARD (disease-modifying antirheumatic drugs) inklusive Methotrexat zur Behandlung von Kindern und Jugendlichen ab 2 Jahren bis 17 Jahren mit systemischer juveniler idiopathischer Arthritis (sJIA), welche auf eine vorgängige Therapie mit nicht-steroidalen Antirheumatika und Steroiden nicht ausreichend angesprochen haben.
In Kombination mit Methotrexat zur Behandlung von Kindern und Jugendlichen ab 2 Jahren bis 17 Jahren mit aktiver polyartikulärer juveniler idiopathischer Arthritis (pJIA), die auf eine vorgängige Therapie mit Methotrexat nicht ausreichend angesprochen haben. Bei einer Unverträglichkeit auf Methotrexat kann TOCILIZUMAB SPIRIG HC als Monotherapie verabreicht werden.
More preparations in this group
FAQ
Is Tocilizumab Spirig HC covered by Swiss health insurance?
Yes, but only under conditions. Tocilizumab Spirig HC is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Tocilizumab Spirig HC cost in Switzerland?
The public price is the maximum price set by the FOPH and for Tocilizumab Spirig HC ranges from CHF 108.15 to CHF 475.05 per pack. The ex-factory price ranges from CHF 84.34 to CHF 421.71. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages